SCHEMBL23218841

SCHEMBL23218841

CCOC(=O)Cc1ccc(CC)cc1OCc1c(C)oc2ccc(Br)cc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.41
KMT2A Q03164 4/20 0.41
MEN1 O00255 3/20 0.40
SLC26A4 O43511 1/20 0.40
BLM P54132 1/20 0.40
ATM Q13315 1/20 0.40
LMNA P02545 4/20 0.39
TSHR P16473 3/20 0.39
P2RX3 P56373 2/20 0.39
ALOX5 P09917 3/20 0.38
CA12 O43570 1/20 0.38
CA9 Q16790 1/20 0.38
ALDH1A1 P00352 3/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
KCNH2 Q12809 2/20 0.36
KDM4E B2RXH2 1/20 0.36
POLB P06746 1/20 0.36
GAA P10253 1/20 0.36
HPGD P15428 1/20 0.36
ALOX12 P18054 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29852573 1.00 MAPT (0.41) MAPTKMT2AMEN1SLC26A4BLM
SCHEMBL23218063 0.90 CA12 (0.39) MAPTKMT2AMEN1SLC26A4BLM
SCHEMBL29853022 0.90 CA12 (0.39) MAPTKMT2AMEN1SLC26A4BLM
SCHEMBL29853064 0.89 ALOX5 (0.40) MAPTKMT2AMEN1SLC26A4BLM
SCHEMBL23218983 0.89 ALOX5 (0.40) MAPTKMT2AMEN1SLC26A4BLM
SCHEMBL23218119 0.88 TSHR (0.47) MAPTKMT2AMEN1SLC26A4BLM
SCHEMBL29852651 0.88 TSHR (0.47) MAPTKMT2AMEN1SLC26A4BLM
SCHEMBL29591257 0.88 TSHR (0.47) MAPTKMT2AMEN1SLC26A4BLM
SCHEMBL23219259 0.87 TBXAS1 (0.41) MAPTKMT2AMEN1SLC26A4BLM
SCHEMBL29853250 0.87 TBXAS1 (0.41) MAPTKMT2AMEN1SLC26A4BLM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 US disclosed
EP-4041238-A1 ORAL COMPLEMENT FACTOR D INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2022-08-17 EP disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB MAPT 4793/4885KMT2A 4445/4885MEN1 1819/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB MAPT 3561/4885KMT2A 4835/4885MEN1 548/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.